Back to search
FDAFDA · Food and drugs·Recall number D-0507-2025

Gabapentin Capsules, USP, 100 mg, 100 capsules (10x10), blister pack cartons, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN, 46268 USA, NDC 0904-6665-61

Published July 9, 2025 · Recall initiated: June 19, 2025

Summary

FDA records drug Class II recall D-0507-2025, published July 9, 2025 and initiated June 19, 2025. Recalling firm: The Harvard Drug Group LLC; Status: Ongoing; Reported quantity: 23,232 cartons; Lot: Lot# M05205, Exp Date 10/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Defective container; blister packaging inadequately sealed.

What to do

Voluntary: Firm initiated · Letter

Get an email if GABAPENTIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
GABAPENTIN
Manufacturer
The Harvard Drug Group LLC
Distributor
Nationwide
Lot
Lot# M05205, Exp Date 10/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Gabapentin Capsules, USP, 100 mg, 100 capsules (10x10), blister pack cartons, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN, 46268 USA, NDC 0904-6665-61 recalled?

Yes. FDA published recall D-0507-2025 on July 9, 2025. Reported hazard: Defective container; blister packaging inadequately sealed.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: GABAPENTIN.